Phone: 888-558-5227

651-644-8424

888-558-7329 Fax: Email: getinfo@lktlabs.com

Web: lktlabs.com

Product Information

Product ID A0778

CAS No. 852808-04-9

Chemical Name

Synonym ABT737

Formula C₄₂H₄₅ClN₆O₅S₂

Formula Wt. 813.43

Melting Point

Purity ≥98%

Solubility DMSO 100 mg/mL (122.93

mM)

Water Insoluble Ethanol Insoluble

Store Temp -20°C Ship Temp Ambient

Description ABT-737 is a BH3 mimetic that acts as an inhibitor of Bcl-2, Bxl-xl, and Bcl-ω. ABT-737 exhibits anticancer chemotherapeutic

and antithrombotic activities. ABT-737 is currently in clinical trials as one component of a combination therapy in the treatment of various cancers such as acute myelogenous leukemia (AML). This compound inhibits growth of AML cells in vitro and increases survival rates and lifespan in animal models of AML. In vitro, ABT-737 induces mitochondrial membrane

depolarization in platelets, inducing apoptosis and clearance.

Bulk quanitites available upon request

Product ID	Size
A0778	1 mg
A0778	5 mg
A0778	10 mg

References Lieber J, Armeanu-Ebinger S, Fuchs J. The Role of BH3-Mimetic Drugs in the Treatment of Pediatric Hepatoblastoma. Int J Mol Sci. 2015 Feb 16;16(2):4190-4208. PMID: 25690034.

> Baev DV, Krawczyk J, O'Dwyer M, et al. The BH3-mimetic ABT-737 effectively kills acute myeloid leukemia initiating cells. Leuk Res Rep. 2014 Sep 1;3(2):79-82. PMID: 25379408.

> Gyulkhandanyan AV, Mutlu A, Allen DJ, et al. BH3-mimetic ABT-737 induces strong mitochondrial membrane depolarization in platelets but only weakly stimulates apoptotic morphological changes, platelet shrinkage and microparticle formation. Thromb Res. 2014 Jan;133(1):73-9. PMID: 24268298.

> Beurlet S, Omidvar N, Gorombei P, et al. BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells. Blood. 2013 Oct 17;122(16):2864-76. PMID: 23943652.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.